ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Bosnian Research Trying To Leave, Asks For More Calls

February 5, 1993

NCCN Updates Myeloma Clinical Practice Guidelines

September 26, 2003

Cancer Documentary Provides Argument for Increased Funding

May 23, 1986

Charles Balch resigns as ASCO executive vice president; Joseph Bailes named interim EVP.

October 28, 2005

Two New Communications Contracts Approved

October 18, 1985

Schilskly Promoted to Associate Dean At Chicago, Vogelzang To Direct Center

March 5, 1999